Initial Visual Acuity Is an Important Prognostic Factor in Patients with Branch Retinal Vein Occlusion

Jiri Rehak a  Ladislav Dusek b  Oldrich Chrapek a  Evzen Fric a  Matus Rehak c

a Department of Ophthalmology, University Hospital, Palacky University, Olomouc, and b Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic; c Department of Ophthalmology, University of Leipzig, Leipzig, Germany

Abstract

**Purpose:** To evaluate the role of initial visual acuity (VA) as a potential prognostic factor for final VA in patients with branch retinal vein occlusion (BRVO).

**Methods:** A retrospective data analysis involving 163 patients with macular edema secondary to BRVO treated according to the recommendations of the Branch Vein Occlusion Study Group was performed using univariate and multivariate logistic regression models, and receiver-operating characteristics analysis. The analyses take factors into account that can potentially influence final visual result: sex, age, type of occlusion (major temporal or macular), grid photocoagulation and ischemia.

**Results:** The final VA ≤0.1 was statistically significantly related to initial VA ≤0.16 and age >70 years. Sex, type of occlusion, grid photocoagulation and ischemia did not significantly influence the prediction of final VA based on age and initial VA.

**Conclusions:** The analysis shows that initial VA and age >70 years significantly influence the prognosis for final visual results in patients with BRVO.

Introduction

In general, branch retinal vein occlusion (BRVO) has a good prognosis; 50–60% of eyes have been reported to have a final visual acuity (VA) of ≥0.5 even without any treatment [1–3]. Chronic macular edema (ME) and bleeding into the vitreous from neovascularizations account most frequently for a poor final VA [4, 5]. Gutman [5] found that in the natural course of BRVO, only 14% of eyes with chronic ME retained a VA of ≥0.5, while 86% had a final VA of ≤0.4. He concluded that chronic ME has a poor prognosis in terms of final VA. A worse visual prognosis has been reported in cases with ischemic ME than perfused ME in some studies [6, 7] but not in others [8]. Generally, it is difficult to predict the visual prognosis for patients with BRVO in the acute phase of the disease. The conflicting reports and small patient numbers in currently published studies make any definitive conclusions about prognostic factors for VA in BRVO patients difficult. Various prognostic factors for BRVO patients have been assessed, e.g. the correlation between macular thickness measured by optical coherence tomography and VA [9] or that between VA and the integrity of the outer photoreceptor layer detected by optical coherence tomography [10]. In patients with central retinal vein occlusion, the initial VA has been shown as a strong prognostic factor for the final VA [11, 12].
In our previously published review [13], we analyzed studies that reported the visual results in patients with BRVO [1, 2, 14–16]. Our review showed that eyes with an initial VA ≥ 0.4 have a good visual prognosis even without any treatment. The percentage of final VA ≤ 0.1 was significantly higher (30–83%) in patients with an initial VA ≤ 0.1 than the 0–25% of eyes in those with an initial VA ≥ 0.4 [13]. However, methodological differences in the studies analyzed obfuscate definitive conclusions.

For this reason, we realized a retrospective study on our own BRVO patient group with the aim to analyze the role of pretreatment VA as a potential prognostic factor for final VA. Further, we evaluated whether patient sex, age, type of occlusion (major temporal or macular), ischemic status or use of grid laser photocoagulation significantly contribute to the prediction of final VA in BRVO.

**Material and Methods**

The retrospective data analysis investigated the relation between initial and final VA in patients with BRVO with a follow-up of 1 year. In total, 221 eyes of 221 patients were assigned to the treatment schedule according to the recommendations of the Branch Vein Occlusion Study Group (BVO SG) in the period from 1987 to 2007 at the Department of Ophthalmology, Palacky University, Olomouc. All these patients were screened for eligibility in the present study. Additional to ophthalmic laser treatment, all cases also had subsidiary medical therapy with 100 mg salicylic acid (1), 100 mg pentoxifylline (3), 1), 100 mg aspirin (1), 100 mg edaravone (1), 0.5 mg dexamethasone (1), 3.5 mg prednisolone (1), 0.5 mg bevacizumab (1) and 0.4 mg ranibizumab (1) for treatment of neovascular age-related macular degeneration, which was not included in the analysis. For this reason, we realized a retrospective study on our own BRVO patient group with the aim to analyze the role of pretreatment VA as a potential prognostic factor for final VA. Further, we evaluated whether patient sex, age, type of occlusion (major temporal or macular), ischemic status or use of grid laser photocoagulation significantly contribute to the prediction of final VA in BRVO.

Visual Acuity as Prognostic Factor for BRVO

**Statistics**

Standard measures of summary statistics were used to describe data: relative and absolute frequencies, median and 5th–95th percentile range. Robust nonparametric Kruskal-Wallis and Mann-Whitney U tests were used to evaluate the differences among groups of patients in VA and age. The ML χ² and Fisher exact tests were used to test the differences in categorical parameters (gender, categories of VA, occurrence of ischemia, type of BRVO major/macular and grid photocoagulation yes/no). The diagnostic predictive power of all examined parameters was finally assessed on the basis of the receiver-operating characteristic (ROC) curves using categories of VA in 1 year as endpoint. The ROC analysis was performed using an ROC web calculator [17] for curve fitting, SPSS 17.02 [18] for the area-under-the-curve computation and testing and Medcalc 11.1.0.0 (Medcalc Software 1993–2009) for computation of confidence intervals for sensitivity and specificity. The computation was based on binormal distribution assumptions. Both univariate and multivariate logistic regression strategies were applied to quantify the association of examined prognostic factors with VA in 1 year. The odds ratio with 95% confidence intervals was estimated and tested in the Wald χ² test. Parameters with potential risk power (providing at least p ≤ 0.10 in univariate logistic regression) were then examined for mutual correlation, and interaction terms were coded and tested for significantly correlated pairs of variables. Effective cutoff values of continuous variables (age, VA) were optimized on the basis of the ROC analysis. The final set of potential prognostic factors and interaction terms (coded as binary variables according to the cutoff points) were subjected to a stepwise selection algorithm in multivariate logistic regression (driven by the maximum likelihood ratio test).

**Results**

The total sample comprised 221 eyes. Forty-seven patients were excluded from the statistical analysis according to the defined exclusion criteria. A further 11 patients were excluded due to loss to follow-up for at least 12 months.

A total of 163 eyes of 163 patients (84 female and 79 male) were analyzed. The mean age of all patients was 62 years (range 47–80 years). The baseline characteristics of all investigated patients are shown in table 1. The changes in best-corrected VA during the follow-up of 1 year in
all analyzed patients are shown in Figure 1. The median value of initial VA in patients without laser treatment was 0.42 (5th–95th percentile range: 0.016–1.0) and the median value of final VA after 1 year was 0.61 (0.016–1.0). Treatment with grid laser photocoagulation was performed in 71 eyes (43.6%). The median value of initial VA in these patients was 0.27 (0.016–0.5) and the median value of final VA 1 year after inclusion into the study was 0.43 (0.016–1.0). In 35 eyes (21.5%), repeated grid laser photocoagulation was done. The grid photocoagulation was repeated in 21 eyes (12.9%) once, in 10 eyes (6.1%) twice and in 4 eyes (2.5%) 3 times. Ninety-two eyes (56.4%) were observed only and did not receive grid photocoagulation because the BVO SG criteria for grid laser treatment were not met. Scatter laser photocoagulation in areas of retinal nonperfusion was required due to the presence of neovascularization of the disk or elsewhere in 28 (17.2%) of all eyes: in 8 (28.6%) eyes treated with grid photocoagulation and in 20 (71.4%) observed eyes. In 3 (1.8%) cases, we noted temporary intravitreal hemorrhage (1 eye from the grid laser group and 2 eyes from the observed group). VA ≤0.1 at the 1-year visit (n = 37) was predominantly associated with dry macula and severe changes in the retinal pigment epithelial layer (very likely associated with photoreceptor loss) in 25 cases (67.6%), and further in 8 patients with persistent chronic ME unimproved after repeated laser treatment (21.6%) and in 4 cases with insufficient resorption of retinal hemorrhage in the foveal region (10.8%).

The descriptive analysis showed that although the median value for final VA was 0.66, 22.7% of patients reached a final VA of only ≤0.1 (Table 1). Therefore, the risk of this poor final visual outcome is frequent, justifying the development of prognostic models. Initial descriptive analysis also indicated frequent intercorrelations between vari-

---

**Table 1.** Baseline characteristics of patients

<table>
<thead>
<tr>
<th>Parameters</th>
<th>All patients (n = 163)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex, %</td>
<td>48.5 (n = 79)</td>
</tr>
<tr>
<td>Age, years</td>
<td>62 (range 47–80)</td>
</tr>
<tr>
<td>&gt;70 years, %</td>
<td>23.3 (n = 38)</td>
</tr>
<tr>
<td>Ischemia, %</td>
<td>34.4 (n = 56)</td>
</tr>
<tr>
<td>Patients underwent grid laser photocoagulation, %</td>
<td>43.6 (n = 71)</td>
</tr>
<tr>
<td>Major BRVO, %</td>
<td>80.4 (n = 131)</td>
</tr>
<tr>
<td>Initial VA ≤0.1, %</td>
<td>27.6 (n = 45)</td>
</tr>
<tr>
<td>Initial VA in 1 year ≤0.1, %</td>
<td>22.7 (n = 37)</td>
</tr>
</tbody>
</table>

Categorical variables are summarized as number and percentage of a given category; quantitative variables are described by medians and by 5th–95th percentile ranges.

---

**Table 2.** Analysis of risk factors for final VA ≤0.1 based on results of univariate logistic regression models

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Final VA in 1 year ≤0.10</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
</tr>
<tr>
<td>Male sex</td>
<td>0.49 (0.23–1.06)</td>
</tr>
<tr>
<td>Age</td>
<td>1.12 (1.07–1.17)</td>
</tr>
<tr>
<td>&gt;70 years</td>
<td>8.42 (3.66–19.36)</td>
</tr>
<tr>
<td>Major BRVO</td>
<td>3.39 (0.96–11.95)</td>
</tr>
<tr>
<td>Ischemia</td>
<td>1.89 (0.89–4.03)</td>
</tr>
<tr>
<td>Grid laser</td>
<td>1.99 (0.94–4.22)</td>
</tr>
<tr>
<td>Initial VA ≤0.1</td>
<td>9.23 (4.03–21.12)</td>
</tr>
<tr>
<td>Initial VA ≤0.16</td>
<td>15.17 (5.75–40.00)</td>
</tr>
</tbody>
</table>

OR = Odds ratio; 95% confidence intervals are given in parentheses. Statistically significant results (p < 0.05) are marked with an asterisk.
Visual Acuity as Prognostic Factor for BRVO

Variables which were tested as potential prognostic factors for final VA in 1 year. An initial VA ≤0.1 was significantly associated with major type of occlusion: 44 (97.8%) versus 1 (2.2%) in macular BRVO. A significantly higher incidence of ischemia was observed in major BRVO, with 52 (92.6%) versus 4 (7.1%) in macular BRVO. Age was found to be the most significant factor for most of the following examined variables: type of occlusion, grid laser photocoagulation, retinal ischemia, and initial VA. For this reason, age was used in all model predictions of the final VA.

Table 2 summarizes univariate logistic regression models in terms of odds ratio and corresponding confidence intervals. The results indicate that only age and initial VA have a statistically significant association with the prognostic factors for final VA ≤0.1. The other investigated factors did not reach a statistically significant odds ratio. Age was highly significantly associated both quantitatively in years and as a code around point 70 years. We performed the ROC analysis (table 3) to assess the diagnostic potential of investigated factors in relation to final VA. The ROC analysis confirmed the significant discrimination potential for final VA score in case of age >70 years and for categories of initial VA. All the other potential prognostic factors did not reach recognizable area-under-the-curve values, sensitivity, and/or specificity. Regarding initial VA as a potential predictor, the ROC analysis proved the diagnostic power of category of initial VA ≤0.16 as the most significant (it reached peak values of area under the curve, a sensitivity of 83.8% and a specificity of 74.6%).

The multivariate logistic regression model for risk endpoint VA in 1 year ≤0.1 showed that only age >70 years and initial VA ≤0.16 were significant and mutually independent terms of the predictive formula. The stepwise calculation procedure started with all examined variables, but none of the other variables reached significant multivariate adjusted odds ratios.

We can conclude that an initial VA ≤0.16 was confirmed as a significant predictor of final VA ≤0.10 in both univariate and multivariate models (not shown) and in the ROC analysis as well.

The other factors which were not included in the multivariate model (sex, occlusion type major/macular, grid photoagulation yes/no and ischemia yes/no) did not reach a significant age-adjusted odds ratio.

As the initial VA significantly influenced the final visual result, we divided our BRVO patients according to initial VA into 3 subgroups: A ≤0.4; B 0.3–0.16, and C ≤0.1. Median values and 5th–95th percentile range of VA in 1 year were as follows: A = 0.66 (0.10–1.00), B = 0.40 (0.03–0.66), C = 0.10 (0.016–0.50). The final VA score was statistically significantly different among groups and the groups were found to be mutually statistically significantly different (p < 0.001; fig. 2).

Discussion

Generally, the visual prognosis for patients with BRVO is relatively good but exact prognosis remains difficult. The most frequent cause of visual impairment is chronic ME which develops from complex intracellular and extracellular changes in a hypoxic retina [19]. Even when the occluded region does not directly involve the macula, other extracellular factors (such as vascular endothelial growth factor or interleukins) contribute to the
The development of ME [20]. Some authors even claim that the course of the occlusion cannot be predicted [2, 21, 22]. In our previous review of published studies [13], we showed that the percentage of a final VA \( \leq 0.1 \) was significantly higher in patients with an initial VA \( \leq 0.1 \) than in eyes with an initial VA \( \geq 0.4 \). Other authors have also speculated that pretreatment VA might influence the VA after laser photocoagulation in patients with ME due to BRVO [23]. Therefore, we performed the above retrospective analysis of our own BRVO patients with the aim of evaluating the role of initial VA as a prognostic factor for final VA.

The grid laser photocoagulation was indicated according to the recommendation of the BVO SG [21]. All patients also had subsidiary treatment with pentoxifylline, salicylic acid and ascorbic acid. Although the evidence for this subsidiary treatment is weak, some authors have reported a possible benefit of rheological and anti-thrombotic therapy [24]. Since all eyes received this treatment, it did not influence the statistical evaluation.

Both univariate and multivariate analyses proved initial VA to be a significant predictor for the final VA. The ROC analysis confirmed an initial VA \( \leq 0.16 \) as the most significant predictor of risk VA outcome with the highest sensitivity and specificity. We can draw the important conclusion that pretreatment VA influences the final VA in patients with ME due to BRVO. We consider a BRVO prognostically unfavorable in terms of final visual result for those occlusions with an initial VA \( \leq 0.16 \). The ROC analysis also revealed that the prognostic value of initial VA is increased above a patient age \( > 70 \) years. Our analyses also showed that sex, occlusion type, ischemic type of BRVO and grid laser treatment did not significantly contribute to the constructed models for predicting final VA.

The rate of poor final visual result (\( \leq 0.1 \)) varies widely in the literature from 12 to 46% [1–3, 6, 14–16, 21, 25]. This fact points to methodological discrepancies in the way the results were evaluated in these studies. The rates of poor final VA in treated patients have been reported in some studies to be between 31 and 46% [14, 22, 25] and to exceed the rates in untreated groups of 19–23% [1, 3, 21]. This might indicate that laser treatment leads to poorer visual results. The apparent paradox can be explained by our analyses. These studies differed considerably in the rate of eyes with poor initial VA, and, as we found, initial VA significantly influences the final visual result. If the study group comprises a higher percentage of eyes with poor initial VA, the poorer would be the prognosis. Esrick et al. [26] published data in which they used the same treatment schedule as the BVO SG [21], but the results differed significantly. Only 46.6% of the patients of Esrick et al. [26] gained 2 or more lines of vision compared to 65% if those of the BVO SG [21]. Esrick et al. [26] suggest that these differences may be due to a number of factors, including the poorer average prelaser VA in their patients. Glacet-Bernard et al. [11] evaluated prognostic factors in 48 cases of BRVO and concluded that older age and reduced baseline VA were correlated with poor visual prognosis. The results of our analysis are in agreement with the results of studies which evaluated predictive factors for visual improvement in patients with BRVO treated with bevacizumab [27, 28]. Jaissle et al. [28] showed that younger patients (\( < 60 \) years) and initial VA \( \leq 0.5 \) logMAR (which correlates with \( \geq 0.32 \) in Snellen charts) are significantly associated with a good visual outcome. Therefore, the age and initial VA seem to be useful prognostic factors for the final VA not only in patients without any treatment or treated with grid laser photocoagulation, but also for cases treated with bevacizumab.
Conclusions

This study shows that initial VA predicts final visual results in patients with BRVO. We consider a BRVO prognostically unfavorable for the final VA ($\leq 0.1$) in patients with an initial VA of $\leq 0.16$. The results of this study and analysis of the published data suggest caution in the interpretation of different treatment evaluations in patients with BRVO. To compare the impact of two different treatment methods on VA, it is essential that the comparison is only among eyes with similar initial VA. We recommend dividing the patients with BRVO into 3 groups according to initial VA: $\geq 0.4$, $0.3–0.16$ and $\leq 0.1$.

References